Breaking Finance News

Albany Molecular (NASDAQ:AMRI) has been downgraded from Overweight to Neutral in a statement by JPMorgan earlier today.

Boasting a price of $21.70, Albany Molecular (NASDAQ:AMRI) traded -100.00% lower on the day. With the last close up 18.06% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Albany Molecular has recorded a 50-day average of $21.72 and a two hundred day average of $18.41. Volume of trade was down over the average, with 531,221 shares of AMRI changing hands under the typical 1,270,940

JPMorgan has downgraded Albany Molecular (NASDAQ:AMRI) from Overweight to Neutral in a statement released on Thursday June 08, 2017.

Performance Chart

Albany Molecular (NASDAQ:AMRI)

With a total market value of $0, Albany Molecular has with a 52 week low of $13.01 and a 52 week high of $22.17 .

General Information About Albany Molecular (NASDAQ:AMRI)

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *